Traders Buy Large Volume of Capricor Therapeutics Put Options (NASDAQ:CAPR)

Capricor Therapeutics Inc (NASDAQ:CAPR) was the target of unusually large options trading on Friday. Stock investors purchased 7,897 put options on the company. This is an increase of 62% compared to the average daily volume of 4,879 put options.

Institutional Investors Weigh In On Capricor Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Summit Investment Advisors Inc. lifted its position in shares of Capricor Therapeutics by 54.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 1,345 shares in the last quarter. Russell Investments Group Ltd. raised its position in Capricor Therapeutics by 172.8% in the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 2,947 shares during the last quarter. Virtus ETF Advisers LLC acquired a new position in Capricor Therapeutics during the 4th quarter worth $68,000. AlphaQuest LLC acquired a new position in Capricor Therapeutics during the 4th quarter worth $78,000. Finally, New York State Common Retirement Fund boosted its position in Capricor Therapeutics by 625.0% in the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 5,000 shares during the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

Analyst Ratings Changes

CAPR has been the subject of several analyst reports. Roth Capital assumed coverage on Capricor Therapeutics in a research report on Tuesday, May 20th. They set a “buy” rating and a $31.00 target price for the company. Wall Street Zen cut Capricor Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. Cantor Fitzgerald restated an “overweight” rating and issued a $30.00 target price on shares of Capricor Therapeutics in a research note on Wednesday, May 14th. Finally, HC Wainwright reiterated a “buy” rating and set a $77.00 target price on shares of Capricor Therapeutics in a research report on Friday. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $35.50.

Capricor Therapeutics Price Performance

CAPR stock opened at $11.78 on Friday. The business has a fifty day moving average price of $10.72 and a 200 day moving average price of $12.77. Capricor Therapeutics has a fifty-two week low of $3.52 and a fifty-two week high of $23.40. The stock has a market capitalization of $538.08 million, a price-to-earnings ratio of -11.11 and a beta of 0.84.

Capricor Therapeutics (NASDAQ:CAPR) last announced its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.20). Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The business had revenue of $2.73 million during the quarter, compared to analyst estimates of $3.16 million. During the same quarter last year, the business posted ($0.31) earnings per share. On average, equities analysts expect that Capricor Therapeutics will post -1.21 earnings per share for the current fiscal year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.